-
Mashup Score: 0COVID-19 Guideline, Part 1: Treatment and Management - 12 month(s) ago
IDSA has developed living, frequently updated evidence-based guidelines to support patients, clinicians and other health-care professionals in their decisions about treatment and management of patients with COVID-19 infection. Summarized here are the recommendations with comments related to the clinical practice guideline for the treatment and management of COVID-19.
Source: www.idsociety.orgCategories: Infectious Disease, Latest HeadlinesTweet
-
Mashup Score: 7COVID-19 Guideline, Part 1: Treatment and Management - 12 month(s) ago
IDSA has developed living, frequently updated evidence-based guidelines to support patients, clinicians and other health-care professionals in their decisions about treatment and management of patients with COVID-19 infection. Summarized here are the recommendations with comments related to the clinical practice guideline for the treatment and management of COVID-19.
Source: www.idsociety.orgCategories: Infectious Disease, Latest HeadlinesTweet-
IDSA has released a new recommendation on #anakinra and updated remarks for the existing recommendation on the use of #nirmatrelvir/#ritonavir in the treatment of patients with COVID-19. 📝: https://t.co/InyRvQiYjp #IDSAGuidelines #COVID19Guidelines https://t.co/hxn2g9ZoOz
-
-
Mashup Score: 0Lopinavir/ritonavir for Treatment of Non-Hospitalized Patients with COVID-19: A Randomized Clinical Trial - 1 year(s) ago
Introduction
Categories: Latest Headlines, PulmonologyTweet-
#Lopinavir/ #ritonavir for #Treatment of Non-Hospitalized #Patients with #COVID-19: A Randomized #Clinical #Trial https://t.co/lXGdnQmD3c https://t.co/H9XRXhbsDw
-
-
Mashup Score: 0Wolters Kluwer Health - 1 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Emergency Medicine, Latest HeadlinesTweet-
Our best-read article last March: #Ritonavir/nirmatrelvir & #molnupiravir were approved by the @US_FDA to treat #COVID19, and @poisonreview explained how to use these oral drugs. #FOAMtox #FOAMed https://t.co/XRJ1dU8njJ #Bestof2022 https://t.co/aJadiq6KIk
-
-
Mashup Score: 3
Background: In the EPIC-HR (Evaluation of Protease Inhibition for Covid-19 in High-Risk Patients) trial, nirmatrelvir plus ritonavir led to an 89% reduction in hospitalization or death among unvaccinated outpatients with early COVID-19. The clinical impact of nirmatrelvir plus ritonavir among vaccinated populations is uncertain. Objective: To assess whether nirmatrelvir plus ritonavir reduces…
Source: Annals of Internal MedicineCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
Study of 44k nonhospitalized persons w/ #COVID19 found #nirmatrelvir plus #ritonavir reduced the overall risk of hospitalization and death: https://t.co/tBxUUvCyPM #paxlovid https://t.co/9QVu7jGECy
-
-
Mashup Score: 3
A patient with B-cell acute lymphoblastic leukemia (ALL) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had persistent, progressive pneumonia with viremia after 5 months of infection despite monoclonal antibodies, IV remdesivir and prolonged oral steroids. Twenty days of nirmatrelv …
Source: PubMedCategories: Latest Headlines, PulmonologyTweet-
Successful treatment of #prolonged, #severe #COVID-19 #lower #respiratory #tract #disease in a B-cell ALL patient with an #extended #course of #remdesivir and #nirmatrelvir / #ritonavir https://t.co/oP9p0Dpbwu https://t.co/NHVQgadnqR
-
-
Mashup Score: 0Recurrence of Symptoms Following a 2-Day Symptom Free Period in Patients With COVID-19 - 2 year(s) ago
This cohort study of US adults with untreated COVID-19 examines the types and length of symptoms experienced following symptom recurrence.
Source: jamanetwork.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Some patients with COVID-19 who do not receive treatment with #nirmatrelvir - #ritonavir still experience rebound #COVID-19 https://t.co/AfSLYwJWlX via @JAMANetworkOpen part of @JAMANetwork
-
-
Mashup Score: 4Cardiovascular Drug Interactions With Nirmatrelvir/Ritonavir in Patients With COVID-19: JACC Review Topic of the Week - 2 year(s) ago
Abstract Nirmatrelvir-ritonavir (NMVr) is used to treat symptomatic, nonhospitalized patients with coronavirus disease-2019 (COVID-19) who are at high risk of progression to severe disease. Patient…
Categories: Cardiologists, Latest HeadlinesTweet-
Decision-Making Algorithm for Patients on #CV Medications Who Need #Nirmatrelvir-Ritonavir Drug-Drug Interactions of CV Medications With Nirmatrelvir-#Ritonavir https://t.co/Jm46BgZtfe @SarjuGanatraMD @JACCJournals @Steph_Achenbach @AnastasiaSMihai @DrRyanPDaly @iamritu https://t.co/uceIUXO4G4
-
-
Mashup Score: 0
Cochrane Clinical Answers Clinical Answer: For unvaccinated, non‐hospitalized people with symptomatic COVID‐19 at high risk of progression to severe COVID‐19, low‐certainty evidence suggests that fewer people may die and experience worsened clinical status at day 28 with nirmatrelvir/ritonavir compared with placebo (11 and 53 fewer people per 1000, respectively; all results on average)….
Source: www.cochranelibrary.comCategories: General Medicine News, Latest HeadlinesTweet-
#Nirmatrelvir combined with #ritonavir for preventing and treating #COVID19 ➡️ Read the new @CochraneLibrary Clinical Answer: https://t.co/dU8fs8bRug 📃 Read the plain language summary and full review: https://t.co/gy9tPLRaSx #CochraneClinicalAnswers https://t.co/XIaijL5Y8N
-
-
Mashup Score: 0
Little apparent effect observed in patients ages 40 to 64, however
Source: www.medpagetoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Older patients treated w/ #nirmatrelvir boosted by #ritonavir (#Paxlovid) for #COVID19 had lower rates of hospitalization & death compared w/ those not treated w/ the #antiviral during the #Omicron wave: https://t.co/GghCeC41h6 @ArbelRonen @ClalitHealth @ingridhein @MedPageID
-
ICYMI, IDSA has released a new recommendation on #anakinra and updated remarks for the existing recommendation on the use of #nirmatrelvir/#ritonavir in the treatment of patients with COVID-19 📝: https://t.co/InyRvQiYjp #IDSAGuidelines #COVID19Guidelines